Servier agreed to acquire Day One Biopharmaceuticals for roughly $2.5 billion in cash, a deal that transfers marketed pediatric glioma drug Ojemda (tovorafenib) and Day One’s development programs into Servier’s oncology portfolio. Day One’s shares jumped on the premium offer; Servier said the purchase accelerates its strategy to lead in rare cancers by combining Ojemda with its existing assets such as Voranigo. The transaction is expected to close in the second quarter and will be funded through Servier’s cash plus investments.